Welcome to our dedicated page for Bath & Body Works SEC filings (Ticker: BBWI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bath & Body Works, Inc. filings document the public-company record for a Delaware specialty retailer whose common stock trades on the New York Stock Exchange under BBWI. Recent 8-K reports furnish quarterly and full-year operating results, earnings guidance, Regulation FD disclosures, debt redemption notices and executive officer changes.
Proxy materials describe board oversight, director elections, executive compensation, shareholder voting matters and governance practices tied to the company’s Consumer First Formula, brand, product, supply chain and store assets. The filings also identify registered common stock, senior notes disclosures and capital-structure matters for a personal care and home fragrance retail business.
Bogliolo Alessandro reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works director Alessandro Bogliolo received an equity grant of 7,970 shares of common stock. The award was made on June 11, 2026 as an annual grant of restricted stock units to an independent non-employee director. Following this grant, Bogliolo directly holds 24,490 shares of Bath & Body Works common stock.
Javitch Tom reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. reported that Interim CFO Tom Javitch received a grant of 10,309 shares of common stock on June 12, 2026 as a compensation award. The restricted stock units vest 100% on the one year anniversary of June 12, 2026. Following this grant, Javitch directly holds 59,003 common shares.
Bath & Body Works, Inc. held its Annual Meeting of Stockholders on June 11, 2026, where shareholders elected ten directors to one-year terms. Each nominee, including Alessandro Bogliolo and Sarah E. Nash, received substantially more votes for than against, with significant broker non-votes recorded.
Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year, with 178,656,095 shares voting for and 2,033,828 against. An advisory vote on executive compensation passed, receiving 159,868,611 votes in favor, representing 97.35% of votes cast on that proposal.
Bath & Body Works, Inc. executive Veronique Gabai-Pinsky, Chief Brand & Product Officer, filed an initial Form 3 reporting her holdings in the company. She reports direct ownership of 27,594 shares of common stock. A footnote describes an annual grant of restricted stock units vesting over three years, granted June 10, 2026.
Bath & Body Works, Inc. reported the initial share holdings of Chief Commercial Officer Maly Bernstein on a Form 3. Bernstein holds 67,356 shares of common stock directly. These holdings come from prior annual grants of restricted stock units that vest over a three-year schedule.
The footnote explains that the units vest 30% on the first anniversary of the grant date, 30% on the second, and 40% on the third. The total includes 38,402 outstanding shares from a grant dated December 10, 2025 and 28,954 outstanding shares from a grant dated March 12, 2026.
Bath & Body Works, Inc. executive David Andrew Meeting, who serves as SVP, Controller & Principal Accounting Officer, reported his beneficial ownership on a Form 3. He holds 19,794 shares of common stock directly, reflecting his existing equity position rather than a new transaction.
The total includes prior annual grants of restricted stock units that vest 30% on the first anniversary of the grant date, 30% on the second anniversary, and 40% on the third anniversary. These grants include 2,628 outstanding shares granted on March 13, 2024, 5,425 outstanding shares granted on March 13, 2025, and 11,741 outstanding shares granted on March 12, 2026.
Bath & Body Works, Inc. interim CFO Tom Javitch reported his initial equity holdings. He directly owns 48,694 shares of common stock, which include prior annual grants of restricted stock units vesting over three years. These grants comprise 2,299 shares from March 13, 2024, 6,459 shares from March 13, 2025 and 39,936 shares from March 12, 2026.
He also holds fully vested stock options to buy 4,625 shares at an exercise price of $48.6400 per share expiring on March 16, 2031, 2,960 shares at $38.0100 expiring on March 31, 2027, and 5,487 shares at $31.8100 expiring on March 21, 2028. This filing records existing positions rather than new transactions.
Bath & Body Works reported lower Q1 2026 sales but higher GAAP profit driven by one-time items. Net sales were $1,378 million, down 3.2% from $1,424 million a year earlier, with softer U.S. and Canada store and direct sales partly offset by 9.0% growth in International and Other.
Gross profit fell to $587 million from $646 million, and the gross margin declined to 42.6% from 45.4%, reflecting tariffs, inflation, crude oil impacts and mix. GAAP net income rose to $183 million (diluted EPS $0.90) from $105 million ($0.49) largely due to an $88 million interchange fee settlement gain and a $62 million tax benefit.
On an adjusted basis, which excludes these items and other non-recurring gains and charges, net income declined to $65 million and adjusted diluted EPS to $0.32, versus $105 million and $0.49 in Q1 2025. Adjusted operating income fell to $151 million from $209 million. The company generated $244 million in operating cash flow, repaid $284 million of 2027 notes via a make-whole call, ending the quarter with $820 million in cash and $3,613 million in total debt and $544 million of undrawn ABL availability.
Bath & Body Works reported first quarter 2026 results that beat its own guidance while remaining below prior-year levels on an adjusted basis. Net sales were $1.378 billion, down 3% from $1.424 billion a year earlier. Reported diluted EPS rose to $0.90 from $0.49, but after excluding one-time items, adjusted diluted EPS was $0.32 versus $0.49 last year.
Operating income increased to $231 million from $209 million, or $151 million on an adjusted basis. The company reaffirmed full-year 2026 guidance for net sales to decline 4.5% to 2.5% and guided adjusted EPS to $2.40–$2.65, below 2025’s adjusted $3.21, with forecast free cash flow of about $600 million. Chief Financial Officer Eva Boratto will leave on June 12, 2026, and long-time executive Tom Javitch will serve as interim CFO while a search for a permanent successor is underway.
Bath & Body Works, Inc. Chief Supply Chain Officer Thomas E. Mazurek reported routine equity compensation activity. On May 19, 2026, he received 6,616 shares of common stock at $0.00 per share as a grant tied to the vesting of performance stock units originally granted on May 19, 2023. On the same date, 4,127 shares at $16.11 per share were withheld to cover tax withholding obligations related to the vesting of performance and restricted stock units. Following these transactions, he directly holds 115,170.404 shares of Bath & Body Works common stock.